GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » EBITDA per Share
中文

Hologic (Hologic) EBITDA per Share : $4.32 (TTM As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Hologic EBITDA per Share?

Hologic's EBITDA per Share for the three months ended in Dec. 2023 was $1.27. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.32.

During the past 12 months, the average EBITDA per Share Growth Rate of Hologic was -36.20% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -7.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 53.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Hologic's EBITDA per Share or its related term are showing as below:

HOLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37.3   Med: 27.25   Max: 143.3
Current: -7.5

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Hologic was 143.30% per year. The lowest was -37.30% per year. And the median was 27.25% per year.

HOLX's 3-Year EBITDA Growth Rate is ranked worse than
73.29% of 700 companies
in the Medical Devices & Instruments industry
Industry Median: 9.8 vs HOLX: -7.50

Hologic's EBITDA for the three months ended in Dec. 2023 was $306 Mil.

During the past 12 months, the average EBITDA Growth Rate of Hologic was -37.90% per year. During the past 3 years, the average EBITDA Growth Rate was -9.40% per year. During the past 5 years, the average EBITDA Growth Rate was 50.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Hologic was 138.70% per year. The lowest was -37.80% per year. And the median was 33.05% per year.


Hologic EBITDA per Share Historical Data

The historical data trend for Hologic's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic EBITDA per Share Chart

Hologic Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.29 5.65 11.02 8.33 4.46

Hologic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.42 1.55 0.49 1.01 1.27

Hologic EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hologic's EBITDA per Share for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA per Share(A: Sep. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=1110.6/248.831
=4.46

Hologic's EBITDA per Share for the quarter that ended in Dec. 2023 is calculated as

EBITDA per Share(Q: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=305.7/240.214
=1.27

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hologic  (NAS:HOLX) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Hologic EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Hologic's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hologic (Hologic) Business Description

Traded in Other Exchanges
Address
250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Executives
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan director, officer: President and CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell officer: Div. President, GYN Surgical 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders officer: President, Diag. Solutions 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn officer: Principal Accounting Officer 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart director 5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal officer: Div. President, Diagnostics 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin officer: General Counsel 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton officer: Corp. VP, Finance & Acconting 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson officer: Div. Pres., Breast & Skeletal 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken officer: Group President, International 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752

Hologic (Hologic) Headlines

From GuruFocus

Q3 2021 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Hologic Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Hologic Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Hologic Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024